Navigating the Ins and Outs of GE HealthCare Technologies (GEHC) Stock

By Blake Campbell • Wednesday, January 08 10:15 • Permanent Link

Shares of Medical Electronics company GE HealthCare Technologies jumped 3.0% today. With many investors piling into GEHC without a second thought, it may be a good idea to take a closer look at the stock. Here are some quick facts to get you started:

GE HealthCare Technologies has moved 9.5% over the last year, and the S&P 500 logged a change of 23.5%
GEHC has an average analyst rating of buy and is -11.29% away from its mean target price of $96.76 per share
Its trailing earnings per share (EPS) is $3.65
GE HealthCare Technologies has a trailing 12 month Price to Earnings (P/E) ratio of 23.5 while the S&P 500 average is 29.3
Its forward earnings per share (EPS) is $4.67 and its forward P/E ratio is 18.4
The company has a Price to Book (P/B) ratio of 4.71 in contrast to the S&P 500's average ratio of 4.74
GE HealthCare Technologies is part of the Health Care sector, which has an average P/E ratio of 26.07 and an average P/B of 3.53
GEHC has reported YOY quarterly earnings growth of 24.2% and gross profit margins of 0.4%
The company has a free cash flow of $1.82 Billion, which refers to the total sum of all its inflows and outflows of cash over the last quarter
GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, image-guided therapy, X-ray systems, and women's health products. The Ultrasound segment provides medical devices and solutions for screening, diagnosis, treatment, and monitoring of certain diseases in clinical areas, such as radiology and primary care, women's health, cardiovascular, and point of care and handheld ultrasound solutions, as well as surgical visualization and guidance products. The Patient Care Solutions segment provides medical devices, consumables, services, and digital solutions. Its portfolio includes patient monitoring solutions, anesthesia delivery and respiratory care products, electrocardiogram solutions, maternal infant care products, and consumables and services. The Pharmaceutical Diagnostics supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, positron emission tomography, and ultrasound to the radiology and nuclear medicine industry. The segment also provides contrast media pharmaceuticals that are administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes. It has an AI collaboration with Mass General Brigham. The company was formerly known as GE Healthcare Holding LLC and changed its name to GE HealthCare Technologies Inc. in December 2022. The company was incorporated in 2022 and is headquartered in Chicago, Illinois.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.